Ads
related to: Renal Cell Carcinoma- How This Treatment Works
Learn More About How This
FDA-Approved Treatment Works.
- FAQs
Find FAQs For This Treatment
Option On The Official Patient Site
- Dosing Information
Get Dosing And Treatment
Schedule Information.
- Patient Resources
Find Patient Resources
On The Official Site.
- How This Treatment Works
Search results
Is Moderna Stock A Buy As The Company Eyes The Covid Vaccine Market — Again?
Investor's Business Daily· 1 day agoNow, Moderna stock is pulling back slightly as it forms a cup-with-handle base, MarketSurge.com...
Q&A: Dr. Kimryn Rathmell, director of National Cancer Institute
Nashville Post· 3 days agoDr. W. Kimryn Rathmell earned her stripes while working at Vanderbilt University Medical Center....
Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay
Zacks via Yahoo Finance· 1 day agoThe company plans to present initial findings from retrospective MRD studies at the upcoming...
Courtney Hanneman Of Fredericksburg Dies, 39: 'Pure Love'
Daily Voice· 2 days agoCourtney Hanneman of Fredericksburg died on Tuesday, March 19, according to her obituary on the Mullins & Thompson Funeral Service website. She was 39 years old. Courtney is survived by her husband of 10 years, Timothy, whom …
4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Motley Fool via Yahoo Finance· 5 days agoFor a biotech stock like Exelixis, it means highly predictable cash flow year after year. Lead drug...
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with...
Morningstar· 7 days agoMyriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen ...
HUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading Volume
ETF DAILY NEWS· 2 days agoHUTCHMED (China) Limited (NASDAQ:HCM – Get Free Report) saw unusually-strong trading volume on Monday . Approximately 57,776 shares were traded during mid-day trading, a decline of 52% from ...
Citigroup Inc. Trims Position in BeiGene, Ltd. (NASDAQ:BGNE)
ETF DAILY NEWS· 5 days agoCitigroup Inc. lessened its stake in BeiGene, Ltd. (NASDAQ:BGNE – Free Report) by 15.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission ...
Alan M. Garber Sells 19,205 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock
ETF DAILY NEWS· 2 days agoExelixis, Inc. (NASDAQ:EXEL – Get Free Report) Director Alan M. Garber sold 19,205 shares of the stock in a transaction that occurred on Thursday, March 21st. Following the completion of the ...
JPMorgan Chase & Co. Boosts BeiGene (NASDAQ:BGNE) Price Target to $186.00
ETF DAILY NEWS· 7 days agoBeiGene (NASDAQ:BGNE – Free Report) had its target price increased by JPMorgan Chase & Co. from $184.00 to $186.00 in a report published on Tuesday morning, Benzinga reports. JPMorgan Chase ...
Ads
related to: Renal Cell Carcinoma